Raltegravir in two cats with FeLV: observations and limits of the evidence
Brazilian journal of veterinary medicine · 2022
In plain language
A report describes two cats with naturally acquired FeLV infection that received raltegravir alongside other treatments. In one cat, viral RNA was already undetectable before raltegravir, although viral DNA was detectable. The observations cannot be confidently attributed to raltegravir rather than the course of the infection and the other care the cats received. Not detecting viral material in blood does not prove that the infection is gone.
Scientific detail
The clinical report published in Brazilian journal of veterinary medicine in 2022 (doi: 10.29374/2527-2179.bjvm003522) describes two cats with natural FeLV infection that received raltegravir, an integrase inhibitor. It documents different circulating virological trajectories and provides direct but preliminary feline observations relevant to repurposing this drug for FeLV infection. There was no untreated comparator, and both cats received concurrent treatments.
In case two, viral RNA was undetectable before raltegravir administration despite detectable proviral DNA. This finding, classified as level C evidence in the supplied object, prevents attributing RNA undetectability in this cat to raltegravir. The discordance between detectable proviral DNA and undetectable RNA was already present before drug exposure. Undetectability was assessed in whole blood and does not demonstrate eradication of infection.
The authors acknowledge the small number of cats and insufficient follow-up to assess long-term monotherapy efficacy; this statement is also classified as level C evidence. They also note uncertainty about clinical benefit in cats with probable regressive infection and the absence of controlled studies in naturally infected cats for comparison. The supplied text does not report assay detection limits, pharmacokinetic measurements, or resistance testing. Resistance is discussed as a concern but was not demonstrated in either cat.
The conclusion that the observed virological and clinical changes cannot be confidently attributed to raltegravir rather than the natural course of infection and concurrent care is a methodological inference, with no assigned evidence level. It rests on the uncontrolled design, probable regressive infection status, and concurrent treatment of other conditions; it does not assert that raltegravir had no effect. The report does not constitute controlled evidence of efficacy, elimination of infection, prevention of transmission, improved survival, or established long-term safety.
What we know
The report documents different circulating virological trajectories in two cats with natural FeLV infection. In case two, viral RNA was already undetectable before raltegravir, while proviral DNA was detectable. Both cats received concurrent treatments, and there was no untreated comparator. The authors acknowledge that the sample size and follow-up limit conclusions about sustained efficacy.
What we don't know
It is not possible to determine confidently how much of the observed changes was due to raltegravir rather than the natural course of infection or concurrent care. Clinical benefit in cats with probable regressive infection remains uncertain. This report does not establish long-term efficacy, eradication of infection, prevention of transmission, improved survival, or long-term safety. The supplied text does not report assay detection limits, pharmacokinetic measurements, or resistance testing.
Evidence
EvidenceLevel C — Preliminary evidenceConfidence 100/100
Case two had undetectable viral RNA before raltegravir administration despite detectable proviral DNA.
Excerpt verified in the source — verbatim, in the source's own language“However, when quantitative PCR was performed for both RNA and proviral DNA loads, the former was undetectable and the latter was positive (3.3 x10 4 proviral DNA copies/mL of whole blood).”
The baseline RNA result prevents attributing RNA undetectability in this cat to raltegravir. Detectable proviral DNA and undetectable RNA were already discordant before exposure.
EvidenceLevel C — Preliminary evidenceConfidence 100/100
The authors identify the small number of cats and insufficient follow-up for evaluating long-term monotherapy efficiency as limitations.
Excerpt verified in the source — verbatim, in the source's own language“Despite the absence of adverse effects and the outcomes of both current patients, this report was limited due to the number of cats. Moreover, there is a concern over long-term monotherapy efficiency, which was not evaluated due to the short follow-up time.”
The source explicitly limits conclusions about sustained efficacy. Resistance is discussed as a concern, not demonstrated in either reported cat.
InferenceConfidence 95/100
The observed virological and clinical changes cannot be confidently attributed to raltegravir rather than the natural course of infection and concurrent care.
This methodological inference reflects the uncontrolled design, probable regressive infection status, and concurrent treatment of other conditions. It does not assert that raltegravir had no effect.
Provenance
Source: Undetectable proviral DNA and viral RNA levels after raltegravir administration in two cats with natural feline leukemia virus infection.
AVA